Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022. Key highlights include: Net sales of $71.2 million in Q4 2022. Glaucoma net sales of $52.9 million and Corneal Health net sales of $18.3 million in Q4 2022. Gross margin of